Table 2 Distribution of baseline characteristics according to treatment outcome
From: Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern
Early deterioration (7 patients) | Non-early deterioration (26 patients) | p value | |
|---|---|---|---|
Baseline electrophysiological parameters | |||
Pattern of demyelination, number (%) | |||
Pure focal | 5 (71%) | 5 (19%) | 0.02 |
Non-Focal | 2 (29%) | 21 (81%) | |
CMAP amplitude median nerve (median, mV) | 10 (6) | 6 (5) | 0.29 |
MNCV arms (mean, m/s) | 49.7 (10) | 39.6 (12) | 0.08 |
MNCV legs (mean, m/s) | 39.6 (3) | 37.1 (12) | 0.53 |
Number of CB per examined segments (mean) | 0.31 (0.2) | 0.36 (0.2) | 0.70 |
Sensory involvement severity, number (%) | |||
Normal/minor | 4 (57%) | 6 (23%) | 0.19 |
Moderate/severe | 3 (43%) | 20 (77%) | |
SNAP amplitude median nerve (median, μV) | 15 (13) | 7 (10) | 0.13 |
SNCV median nerve (mean m/s) | 52.6 (7) | 40.8 (12) | 0.02 |
Baseline clinical parameters | |||
MRC sum scores (mean) | 49.9(2) | 50.2 (5) | 0.77 |
Grip strength (median, kPa) | 102 (180) | 88 (64) | 0.37 |
INCAT sensory sum score (median) | 6(7) | 9(7) | 0.56 |
INCAT disability score (median) | 3(2) | 4(3) | 0.42 |
Rivermead Mobility Index (median) | 12(3) | 12(6) | 0.91 |